IP Library Granted Patent US 12,499,981
Granted Patent B2
US 12,499,981 · App. 18/752,098 · Granted Dec 16, 2025

Medical fluid delivery system including a mobile platform for patient engagement and treatment compliance

Inventors: Christopher Daniel Gassman (Crystal Lake, IL); Derek Wiebenson (Deerfield, IL)
Assignees: Baxter International Inc.; Baxter Healthcare SA
G16H10/60G06K19/06028G06K19/06037G16H20/17G16H80/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,499,981
App. No.
18/752,098
Filed
Jun 24, 2024
Granted
Dec 16, 2025
Kind
B2
Art Unit
3687
USPC
705/3
Abstract

A platform for patient engagement and treatment compliance is disclosed. In an example, a system includes a home therapy machine configured to perform a renal failure therapy treatment. The system also includes a mobile communication device including an application that enables a patient to select a program type for a future renal failure therapy treatment. The application is configured to determine a short program and a long program are available for the future renal failure therapy treatment and cause a user interface to provide an option to select one of the short program or the long program. The application is also configured to receive a selection of the short program or the long program via the user interface and transmit a message to the home therapy machine, the message indicative of the selection of the short program or the long program for the future renal failure therapy treatment.

Claims (52)

1 . A home therapy system comprising:

a home therapy machine configured to perform renal failure therapy treatments; and

a personal mobile communication device including an application configured to enable a patient to select a program type for a future renal failure therapy treatment, the application being configured to:

determine a short program and a long program are available for the future renal failure therapy treatment, the short program including a first number of cycles for a renal failure therapy treatment and the long program including a second number of cycles for a renal failure therapy treatment, the second number of cycles being greater than the first number of cycles,

cause a user interface to be displayed on the personal mobile communication device, the user interface including an option to select one of the short program or the long program,

receive a selection of the short program or the long program via the user interface, and

transmit a message to the home therapy machine, the message indicative of the selection of the short program or the long program for the future renal failure therapy treatment.

2 . The home therapy system of claim 1 , wherein the personal mobile communication device is communicatively coupled to the home therapy machine via a server and a network, and

wherein the application is configured to transmit the message to the server, which transmits the message to the home therapy machine.

3 . The home therapy system of claim 2 , wherein the server transmits the message to the home therapy machine after confirming the selection of the short program or the long program for the future renal failure therapy treatment will not adversely affect at least one of an accumulation of fluid within the patient, a patient weight, or a patient blood pressure.

4 . The home therapy system of claim 3 , wherein the server blocks the message from being transmitted to the home therapy machine when the selection of the short program or the long program for the future renal failure therapy treatment will adversely affect the at least one of the accumulation of fluid within the patient, the patient weight, or the patient blood pressure.

5 . The home therapy system of claim 4 , wherein the application is configured to receive an alert message from the server, the alert message indicative that the selection of the short program or the long program for the future renal failure therapy treatment will adversely affect the accumulation of fluid within the patient, the patient weight, or the patient blood pressure.

6 . The home therapy system of claim 1 , wherein the personal mobile communication device is communicatively coupled to the home therapy machine via at least one of a wireless local area network (“WLAN”), a LAN, a Bluetooth™ connection, a WiFi™ connection, a Zigbee® connection, a Z-Wave® connection, or a wireless Universal Serial Bus (“USB”) connection.

7 . The home therapy system of claim 1 , wherein the short program includes a first time duration and a first total volume of dialysis fluid to be provided and the long program includes a second time duration that is longer than the first time duration and a second volume of dialysis fluid to be provided that is greater than the first total volume.

8 . The home therapy system of claim 1 , wherein the application is further configured to:

additionally determine a weekend program is available for the future renal failure therapy treatment, the weekend program including a third number of cycles, the third number of cycles being greater than the first number of cycles and less than the second number of cycles, and

cause the user interface to additionally display the weekend program as a selectable option.

9 . The home therapy system of claim 1 , wherein the short program and the long program are configured to be performed at night while the patient is sleeping.

10 . The home therapy system of claim 9 , wherein the application is further configured to:

additionally determine a day program is available for the future renal failure therapy treatment, and

cause the user interface to additionally display the day program as a selectable option.

11 . The home therapy system of claim 1 , wherein the application is configured to determine the short program and the long program are available for the future renal failure therapy treatment based on a second message from a server indicative that the short program and the long program are available for the patient, and

wherein the server determines the short program and the long program are available using medical data associated with the patient, the medical data including at least one of an estimated accumulation of fluid within the patient, a patient weight trend, or a patient blood pressure trend.

12 . The home therapy system of claim 1 , wherein the home therapy machine includes at least a renal failure therapy machine or an infusion pump, and

wherein the personal mobile communication device is a smartphone, a cellular phone, or a tablet computer.

13 . The home therapy system of claim 1 , wherein the application is further configured to:

display a calendar of scheduled renal failure therapy treatments for the patient; and

cause the user interface to display the option to select one of the short program or the long program after receiving a selection of one of the scheduled renal failure therapy treatments.

14 . A mobile communication device comprising:

a display interface;

a memory storing:

a short program and a long program for renal failure therapy treatments for a patient, the short program including a first number of cycles for a renal failure therapy treatment and the long program including a second number of cycles for a renal failure therapy treatment, the second number of cycles being greater than the first number of cycles, and

instructions defining an application; and

a processor communicatively coupled to the display interface and the memory, the processor configured to execute the instructions to cause the application to:

determine the short program and the long program are available for a future renal failure therapy treatment,

cause a user interface to be displayed on the display interface, the user interface including an option to select one of the short program or the long program,

receive a selection of the short program or the long program via the user interface, and

transmit a message to a home therapy machine, the message indicative of the selection of the short program or the long program for the future renal failure therapy treatment.

15 . The mobile communication device of claim 14 , wherein execution of the instructions by the processor further causes the application to:

display a calendar of scheduled renal failure therapy treatments for the patient; and

cause the user interface to display the option to select one of the short program or the long program after receiving a selection of one of the scheduled renal failure therapy treatments.

16 . The mobile communication device of claim 14 , wherein the mobile communication device is communicatively coupled to a server and a network, and

wherein execution of the instructions by the processor further causes the application to receive the short program and the long program from the server.

17 . The mobile communication device of claim 14 , wherein the execution of the instructions by the processor further causes the application to receive an alert message from a server, the alert message indicative that the selection of the short program or the long program for the future renal failure therapy treatment will adversely affect an accumulation of fluid within the patient, a patient weight, or a patient blood pressure.

18 . The mobile communication device of claim 14 , wherein the memory additionally stores a weekend program, the weekend program including a third number of cycles, the third number of cycles being greater than the first number of cycles and less than the second number of cycles, and

wherein the execution of the instructions by the processor further causes the application to:

determine the weekend program is available for the future renal failure therapy treatment, and

cause the user interface to additionally display the weekend program as a selectable option.

19 . The mobile communication device of claim 14 , wherein the short program and the long program are configured to be performed at night while the patient is sleeping.

20 . The mobile communication device of claim 19 , wherein the execution of the instructions by the processor further causes the application to:

additionally determine a day program is available for the future renal failure therapy treatment, and

cause the user interface to additionally display the day program as a selectable option.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2025
From: BAXTER HEALTHCARE SA
To: VANTIVE HEALTH GMBH
Reel/Frame 073517/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2025
From: BAXTER INTERNATIONAL INC.
To: VANTIVE US HEALTHCARE LLC
Reel/Frame 073517/0702 →
SECURITY INTEREST Recorded Jan 31, 2025
From: VANTIVE US HEALTHCARE LLC; GAMBRO RENAL PRODUCTS, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 070076/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: GASSMAN, CHRISTOPHER DANIEL; WIEBENSON, DEREK
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 068423/0636 →
Continuity (7)
Continuation 18200263 · May 22, 2023
Continuation 17867160 · Jul 18, 2022
Continuation 17215979 · Mar 29, 2021
Division 16561273 · Sep 5, 2019
Continuation In Part 15386913 · Dec 21, 2016
Provisional Application 62727305 · Sep 5, 2018
Related Publication 20240347152A1 · Oct 17, 2024
References Cited (199)
US 4464172A · Lichtenstein · 1984 [cited by applicant]
US 5151082A · Gorsuch et al. · 1992 [cited by applicant]
US 5247434A · Peterson et al. · 1993 [cited by applicant]
US 5486286A · Peterson et al. · 1996 [cited by applicant]
US 5732401A · Conway · 1998 [cited by applicant]
US 5764923A · Tallman et al. · 1998 [cited by applicant]
US 5788851A · Kenley et al. · 1998 [cited by applicant]
US 5867821A · Ballantyne et al. · 1999 [cited by applicant]
US 5919154A · Toavs et al. · 1999 [cited by applicant]
US 5933136A · Brown · 1999 [cited by applicant]
US 6230142B1 · Benigno et al. · 2001 [cited by applicant]
US 6471382B2 · Eichhorn · 2002 [cited by applicant]
US 6685831B2 · Rainer · 2004 [cited by applicant]
US 7044927B2 · Mueller et al. · 2006 [cited by applicant]
US 7072769B2 · Fletcher-Haynes et al. · 2006 [cited by applicant]
US 7185282B1 · Naidoo et al. · 2007 [cited by applicant]
US 7801598B2 · Zhu et al. · 2010 [cited by applicant]
US 7801746B2 · Moll et al. · 2010 [cited by applicant]
US 7890341B2 · McNally et al. · 2011 [cited by applicant]
US 8062513B2 · Yu et al. · 2011 [cited by applicant]
US 8095390B2 · Bluemler et al. · 2012 [cited by applicant]
US 8178040B2 · Brauer · 2012 [cited by applicant]
US 8257582B2 · Yu et al. · 2012 [cited by applicant]
US 8267308B2 · Devergne et al. · 2012 [cited by applicant]
US 8315654B2 · Balschat et al. · 2012 [cited by applicant]
US 8321044B2 · Plahey et al. · 2012 [cited by applicant]
US 8543420B2 · Darby et al. · 2013 [cited by applicant]
US 8632485B2 · Schlaeper et al. · 2014 [cited by applicant]
US 8676660B2 · Yu et al. · 2014 [cited by applicant]
US 8679075B2 · Lurvey · 2014 [cited by applicant]
US 8698741B1 · Wang et al. · 2014 [cited by applicant]
US 8769625B2 · Wang · 2014 [cited by applicant]
US 8823500B2 · Heath · 2014 [cited by applicant]
US 8836519B2 · Wright et al. · 2014 [cited by applicant]
US 8906240B2 · Crnkovich et al. · 2014 [cited by applicant]
US 8926550B2 · Plahey et al. · 2015 [cited by applicant]
US 9081382B2 · Doyle et al. · 2015 [cited by applicant]
US 9178891B2 · Wang et al. · 2015 [cited by applicant]
US 9250216B2 · Wright et al. · 2016 [cited by applicant]
US 9333286B2 · Wright et al. · 2016 [cited by applicant]
US 9408958B2 · Wang et al. · 2016 [cited by applicant]
US 9517295B2 · Wilt et al. · 2016 [cited by applicant]
US 9727696B2 · Case et al. · 2017 [cited by applicant]
US 10380321B2 · Kamen et al. · 2019 [cited by applicant]
US 10391221B2 · Raiford et al. · 2019 [cited by applicant]
US 12295752B2 · Roy · 2025 [cited by examiner]
US 20020040282A1 · Bailey · 2002 [cited by applicant]
US 20020082728A1 · Mueller · 2002 [cited by applicant]
US 20020087361A1 · Benigno et al. · 2002 [cited by applicant]
US 20020103453A1 · Burbank et al. · 2002 [cited by applicant]
US 20020147423A1 · Burbank et al. · 2002 [cited by applicant]
US 20030220598A1 · Busby · 2003 [cited by applicant]
US 20040111294A1 · McNally · 2004 [cited by applicant]
US 20040115132A1 · Young et al. · 2004 [cited by applicant]
US 20040172222A1 · Simpson et al. · 2004 [cited by applicant]
US 20050021370A1 · Riff et al. · 2005 [cited by applicant]
US 20050055242A1 · Bello et al. · 2005 [cited by applicant]
US 20050277890A1 · Stewart et al. · 2005 [cited by applicant]
US 20050277911A1 · Stewart et al. · 2005 [cited by applicant]
US 20070112603A1 · Kauthen et al. · 2007 [cited by applicant]
US 20080040151A1 · Moore · 2008 [cited by applicant]
US 20080154177A1 · Moubayed et al. · 2008 [cited by applicant]
US 20080161751A1 · Plahey et al. · 2008 [cited by applicant]
US 20080215627A1 · Higgins et al. · 2008 [cited by applicant]
US 20080268413A1 · Leichner · 2008 [cited by applicant]
US 20090164248A1 · Hunt · 2009 [cited by applicant]
US 20100010428A1 · Yu et al. · 2010 [cited by applicant]
US 20100137693A1 · Porras · 2010 [cited by applicant]
US 20110004351A1 · Kelly et al. · 2011 [cited by applicant]
US 20110087501A1 · Severin · 2011 [cited by applicant]
US 20110172744A1 · Davis et al. · 2011 [cited by applicant]
US 20110257891A1 · Akonur · 2011 [cited by applicant]
US 20120029937A1 · Neftel · 2012 [cited by applicant]
US 20120041777A1 · Case et al. · 2012 [cited by applicant]
US 20120081225A1 · Waugh · 2012 [cited by applicant]
US 20120138533A1 · Curtis · 2012 [cited by applicant]
US 20120182939A1 · Rajan et al. · 2012 [cited by applicant]
US 20120212455A1 · Kloeffel · 2012 [cited by applicant]
US 20120238851A1 · Kamen · 2012 [cited by applicant]
US 20120289928A1 · Wright et al. · 2012 [cited by applicant]
US 20130018355A1 · Brand et al. · 2013 [cited by applicant]
US 20130020237A1 · Wilt et al. · 2013 [cited by applicant]
US 20130037485A1 · Wilt et al. · 2013 [cited by applicant]
US 20130133036A1 · Wang · 2013 [cited by applicant]
US 20130138452A1 · Cork et al. · 2013 [cited by applicant]
US 20130191513A1 · Kamen et al. · 2013 [cited by applicant]
US 20130211206A1 · Sands et al. · 2013 [cited by applicant]
US 20130297330A1 · Kamen et al. · 2013 [cited by applicant]
US 20130310735A1 · Yu et al. · 2013 [cited by applicant]
US 20130317753A1 · Kamen et al. · 2013 [cited by applicant]
US 20130317837A1 · Ballantyne et al. · 2013 [cited by applicant]
US 20140012595A1 · Fox et al. · 2014 [cited by applicant]
US 20140039447A1 · Wright et al. · 2014 [cited by applicant]
US 20140074506A1 · Oliver et al. · 2014 [cited by applicant]
US 20140091022A1 · Raiford et al. · 2014 [cited by applicant]
US 20140098209A1 · Neff · 2014 [cited by applicant]
US 20140188516A1 · Kamen et al. · 2014 [cited by applicant]
US 20140222450A1 · Gray et al. · 2014 [cited by applicant]
US 20140266983A1 · Christensen · 2014 [cited by applicant]
US 20140267003A1 · Wang et al. · 2014 [cited by applicant]
US 20140289812A1 · Wang et al. · 2014 [cited by applicant]
US 20140298171A1 · Wang et al. · 2014 [cited by applicant]
US 20140299544A1 · Wilt et al. · 2014 [cited by applicant]
US 20140345386A1 · Wright et al. · 2014 [cited by applicant]
US 20150018758A1 · John · 2015 [cited by applicant]
US 20150112264A1 · Kamen · 2015 [cited by applicant]
US 20150154364A1 · Biasi et al. · 2015 [cited by applicant]
US 20150196699A9 · Wilt et al. · 2015 [cited by applicant]
US 20150253860A1 · Merics et al. · 2015 [cited by applicant]
US 20160021191A1 · Wang et al. · 2016 [cited by applicant]
US 20160030655A1 · Wright et al. · 2016 [cited by applicant]
US 20160055303A1 · Keller · 2016 [cited by applicant]
US 20160058933A1 · Ballantyne et al. · 2016 [cited by applicant]
US 20160206800A1 · Tanenbaum et al. · 2016 [cited by applicant]
US 20160239637A1 · Miller · 2016 [cited by examiner]
US 20160261974A1 · Arrizza · 2016 [cited by applicant]
US 20160310653A1 · Wang et al. · 2016 [cited by applicant]
US 20160356874A1 · Wang et al. · 2016 [cited by applicant]
US 20170000938A1 · Wilt et al. · 2017 [cited by applicant]
US 20170011175A1 · Cocks et al. · 2017 [cited by applicant]
US 20170220769A1 · Miller et al. · 2017 [cited by applicant]
US 20180036469A1 · Crnkovich et al. · 2018 [cited by applicant]
US 20180040123A1 · Neff · 2018 [cited by applicant]
US 20190116226A1 · Arrizza · 2019 [cited by applicant]
US 20190154744A1 · Mackinder · 2019 [cited by applicant]
US 20190160227A1 · Li · 2019 [cited by applicant]
US 20190327584A1 · Plahey · 2019 [cited by examiner]
US 20230201434A1 · Weaver · 2023 [cited by examiner]
US 20240221925A1 · Cicchello · 2024 [cited by examiner]
CN 1950125 · 2007 [cited by applicant]
CN 1960775 · 2007 [cited by applicant]
CN 101606157 · 2009 [cited by applicant]
CN 101611409 · 2009 [cited by applicant]
EP 0611228 · 1994 [cited by applicant]
EP 1195708 · 2002 [cited by applicant]
EP 1235614 · 2002 [cited by applicant]
EP 2368588 · 2011 [cited by applicant]
WO 9014850 · 1990 [cited by applicant]
WO 9424929 · 1994 [cited by applicant]
WO 9946657 · 1999 [cited by applicant]
WO 9952025 · 1999 [cited by applicant]
WO 200137786 · 2001 [cited by applicant]
WO 2002078783 · 2002 [cited by applicant]
WO 2004069095 · 2004 [cited by applicant]
WO 2004070546 · 2004 [cited by applicant]
WO 2004070548 · 2004 [cited by applicant]
WO 2004070549 · 2004 [cited by applicant]
WO 2004070556 · 2004 [cited by applicant]
WO 2004070557 · 2004 [cited by applicant]
WO 2004070562 · 2004 [cited by applicant]
WO 2004070994 · 2004 [cited by applicant]
WO 2004070995 · 2004 [cited by applicant]
WO 2005101279 · 2005 [cited by applicant]
WO 2010056712 · 2010 [cited by applicant]
WO 2015183981 · 2015 [cited by applicant]
WO 2016196325 · 2016 [cited by applicant]
Chaudhuri et al. (“Remote treatment monitoring on hospitalization and technique failure rates in peritoneal dialysis patients.” Kidney360 1.3 (2020): 191-202) (Year: 2020). [cited by examiner]
Manns et al., The acu-menTM: A new device for continuous renal replacement therapy in actue renal failure, Kidney International, 1998, pp. 268-274, vol. 54. [cited by applicant]
Supplementary International Search Report for Application No. PCT/US2013/040967 dated Jun. 19, 2014. [cited by applicant]
Letter from Mexican associate regarding office action for MX/a/2007/014394 dated Mar. 12, 2013. [cited by applicant]
European office action for Application No. 11 075 130.2-1651 dated Sep. 23, 2013. [cited by applicant]
European office action for Application No. 11 075 130.2-1651 dated Oct. 6, 2014. [cited by applicant]
Patent Examination Report No. 1—Australia, date of Issue Aug. 18, 2015, Patent Application No. 2013263015—7 pages. [cited by applicant]
Wang, Samuel J. et al. User-Definable Medication Favorites for an Outpatient Electronic Medical Record System. Proc AMIA Symp. 2001 : 1055. [cited by applicant]
Opposition against EP 2368588 (EP Application 11075130.2) mailed May 13, 2016, 30 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/088,966, mailed Jun. 20, 2016, 17 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/135,837, mailed Aug. 12, 2016, 17 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 13/828,900, mailed Aug. 8, 2016, 28 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 13/828,900, mailed Jan. 25, 2016, 28 pages. [cited by applicant]
Office Action issued in CN Application 201380031530.6 mailed Aug. 1, 2016, 12 pages. [cited by applicant]
Office Action issued in AU Application 2013263015 mailed Aug. 16, 2016, 6 pages. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/135,810, mailed Jun. 28, 2016, 18 pages. [cited by applicant]
4008H Hemodialysis Machine Operation Instructions, Software Version 4.2, Fresenius Medical Care. [cited by applicant]
Tsavdaris, et al., “Monitoring and Supporting Home Maemodialysis using Telematic Services”, Decision Support Systems Laboratory, National Technical University of Athens, Wire Communications Laboratory, University of Pat… [cited by applicant]
B. Agroyannis, et al. “Telemedicine technology and applications for home hemodialysis”, The International Journal of Artificial Organs, vol. 22/No. 10, 1999/ pp. 679-683. [cited by applicant]
Contents, The International Journal of Artificial Organs, vol. 22/No. 10—1999/pp. 657-722. [cited by applicant]
Proceedings of the 19th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Oct. 30-Nov. 2, 1997, Chicago, IL USA. [cited by applicant]
Notice of opposition to a European patent, Patent No. EP 1 235 614, dated May 8, 2013. [cited by applicant]
Opposition Statement, Patent No. EP 1 235 614 B, dated May 8, 2013. [cited by applicant]
Notice of opposition to a European patent, Patent No. EP2368588, dated Jun. 14, 2016. [cited by applicant]
Reexamination Certificate, U.S. Pat. No. 5,211,849B1, Certificate Issued May 27, 1997. [cited by applicant]
Decision on Opposition, European Patent No. 1 235 614 dated Jul. 30, 2015. [cited by applicant]
Non-Final Office Action issued Jun. 20, 2016 in U.S. Appl. No. 15/088,966. [cited by applicant]
Final Office Action issued Nov. 25, 2016 in U.S. Appl. No. 15/088,966. [cited by applicant]
Non-Final Office Action issued Jun. 28, 2016 in U.S. Appl. No. 15/135,810. [cited by applicant]
Final Office Action issued Jan. 4, 2017 in U.S. Appl. No. 15/135,810. [cited by applicant]
Non-Final Office Action issued Aug. 12, 2016 in U.S. Appl. No. 15/135,837. [cited by applicant]
Final Office Action issued Feb. 3, 2017 in U.S. Appl. No. 15/135,837. [cited by applicant]
Mexican Office Action issued Dec. 14, 2016 in corresponding Mexican Application No. MX/a/2014/013920. [cited by applicant]
Chinese Office Action issued Feb. 21, 2017 in corresponding Chinese Application No. 201380031530.6. [cited by applicant]
New Zealand Office Action issued Mar. 10, 2017 in corresponding New Zealand Application No. 702249. [cited by applicant]
Canadian Office Action issued Feb. 24, 2017 in corresponding Canadian Application No. 2,873,621—4 pages. [cited by applicant]
International Search Report—PCT/US2017/067662 dated of mailing Jun. 13, 2018—9 pages. [cited by applicant]
Written Opinion of the International Searching Authority—PCT/US2017/067662 dated of mailing Jun. 13, 2018—18 pages. [cited by applicant]
URL:https://hsc.com/Blog/Android-Labs-Bluetooth-HID-device-implementation-your-phone-as-a-mouse-voice-control—Jan. 28, 2015—XP055588550—6 pages. [cited by applicant]
URL:https://en.wikipedia.org/w/index.php?title=USB_human_interface_device_class&oldid=81482617—Dec. 11, 2017—XP055588361—5pages. [cited by applicant]
URL:https://web.archive.org/web/20150508052012/https://hsc.com/Blog/Android-Labs-Bluetooth-HID-device-implementation-your-phone-as-a-mouse-voice-control—4 pages. [cited by applicant]
Letter from Mexican associate regarding office action for MX/a/2007/014394 dated Mar. 12, 2012. [cited by applicant]
Agroyannis et al., “Telemedcine technology and application for home hemodialysis”, Contents, The International Journal of Artificial Organs, vol. 22/No. 10—1999/pp. 657-722. [cited by applicant]